Graham BS - Search Results

1

Graham BS, Modjarrad K, McLellan JS. Graham BS, et al. Curr Opin Immunol. 2015 Aug;35:30-8. doi: 10.1016/j.coi.2015.04.005. Epub 2015 Jun 10. Curr Opin Immunol. 2015. PMID: 26070108 Free PMC article. Review.

2

Clinical trials of HIV vaccines.

Graham BS. Graham BS. Annu Rev Med. 2002;53:207-21. doi: 10.1146/annurev.med.53.082901.104035. Annu Rev Med. 2002. PMID: 11818471 Review.

3

IL-13 is sufficient for respiratory syncytial virus G glycoprotein-induced eosinophilia after respiratory syncytial virus challenge.

Johnson TR, Parker RA, Johnson JE, Graham BS. Johnson TR, et al. Among authors: graham bs. J Immunol. 2003 Feb 15;170(4):2037-45. doi: 10.4049/jimmunol.170.4.2037. J Immunol. 2003. PMID: 12574374

4

Smallpox vaccines: Past, present, and future.

Parrino J, Graham BS. Parrino J, et al. Among authors: graham bs. J Allergy Clin Immunol. 2006 Dec;118(6):1320-6. doi: 10.1016/j.jaci.2006.09.037. J Allergy Clin Immunol. 2006. PMID: 17157663 Free PMC article. Review.

5

TLR9 agonist, but not TLR7/8, functions as an adjuvant to diminish FI-RSV vaccine-enhanced disease, while either agonist used as therapy during primary RSV infection increases disease severity.

Johnson TR, Rao S, Seder RA, Chen M, Graham BS. Johnson TR, et al. Among authors: graham bs. Vaccine. 2009 May 18;27(23):3045-52. doi: 10.1016/j.vaccine.2009.03.026. Epub 2009 Apr 3. Vaccine. 2009. PMID: 19428918 Free PMC article.

6

Structural basis of respiratory syncytial virus neutralization by motavizumab.

McLellan JS, Chen M, Kim A, Yang Y, Graham BS, Kwong PD. McLellan JS, et al. Among authors: graham bs. Nat Struct Mol Biol. 2010 Feb;17(2):248-50. doi: 10.1038/nsmb.1723. Epub 2010 Jan 24. Nat Struct Mol Biol. 2010. PMID: 20098425 Free PMC article.

7

Responses against a subdominant CD8+ T cell epitope protect against immunopathology caused by a dominant epitope.

Ruckwardt TJ, Luongo C, Malloy AM, Liu J, Chen M, Collins PL, Graham BS. Ruckwardt TJ, et al. Among authors: graham bs. J Immunol. 2010 Oct 15;185(8):4673-80. doi: 10.4049/jimmunol.1001606. Epub 2010 Sep 10. J Immunol. 2010. PMID: 20833834 Free PMC article.

8

Structure of a major antigenic site on the respiratory syncytial virus fusion glycoprotein in complex with neutralizing antibody 101F.

McLellan JS, Chen M, Chang JS, Yang Y, Kim A, Graham BS, Kwong PD. McLellan JS, et al. Among authors: graham bs. J Virol. 2010 Dec;84(23):12236-44. doi: 10.1128/JVI.01579-10. Epub 2010 Sep 29. J Virol. 2010. PMID: 20881049 Free PMC article.

9

Biological challenges and technological opportunities for respiratory syncytial virus vaccine development.

Graham BS. Graham BS. Immunol Rev. 2011 Jan;239(1):149-66. doi: 10.1111/j.1600-065X.2010.00972.x. Immunol Rev. 2011. PMID: 21198670 Free PMC article. Review.

10

A West Nile virus DNA vaccine utilizing a modified promoter induces neutralizing antibody in younger and older healthy adults in a phase I clinical trial.

Ledgerwood JE, Pierson TC, Hubka SA, Desai N, Rucker S, Gordon IJ, Enama ME, Nelson S, Nason M, Gu W, Bundrant N, Koup RA, Bailer RT, Mascola JR, Nabel GJ, Graham BS; VRC 303 Study Team. Ledgerwood JE, et al. Among authors: graham bs. J Infect Dis. 2011 May 15;203(10):1396-404. doi: 10.1093/infdis/jir054. Epub 2011 Mar 11. J Infect Dis. 2011. PMID: 21398392 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

578 results

Search Page